Instrumento Inactivo

Otros idiomas CytRx Corporation Other OTC

Acciones

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License	04/06
LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License	04/06
Investor Presentation: June 2024	04/06
LadRx: Q1 Earnings Snapshot	15/05
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C Results in XOMA Making a $1 Million Milestone Payment to LadRx	12/01
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	11/01
LadRx Issues 2024 Update to Shareholders	09/01
LadRx: Q3 Earnings Snapshot	14/11
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
LadRx : Modification to Rights of Security Holders - Form 8-K	11/09/23
LadRx: Q2 Earnings Snapshot	14/08/23
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Investor Presentation: July 2023	15/07/23
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation	22/06/23
LadRx Announces Reverse Stock Split Effective as of May 17, 2023	18/05/23
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
LadRx Announces Reverse Stock Split	10/05/23
LadRx Corporation has filed an IPO in the amount of $24 million.	14/04/23

No hay resultados para esta búsqueda